Positive results from sub-analysis of Eliquis ARISTOTLE trial

7 May 2013

US drug major Bristol-Myers Squibb (NYSE: BMY) and partner Pfizer (NYSE: PFE) reported results from a pre-specified sub-analysis of the ARISTOTLE trial (n=18,201) showing that the reduction in stroke or systemic embolism, number of major bleeding events and mortality demonstrated with Eliquis (apixaban) compared to warfarin were consistent across subgroups defined based on levels of International Normalized Ratio control in patients with non-valvular atrial fibrillation.

Based on the results of the sub-analysis, the benefits of Eliquis (which is already marketed in the USA and Europe) compared with warfarin for stroke or systemic embolism, and mortality appear similar across the range of centers’ and patients’ quality of INR control.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK